AUPH - Aurinia Pharmaceuticals Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$12.60
DETAILS
HIGH:
$16.00
LOW:
$6.00
MEDIAN:
$13.00
CONSENSUS:
$12.60
DOWNSIDE:
24.05%
About Aurinia Pharmaceuticals Inc. (https://www.auriniapharma.com)
Aurinia Pharmaceuticals Inc. operates as a commercial-stage biopharmaceutical company, specializing in the development and commercialization of innovative therapies. Its core mission is to address a variety of diseases for which current medical solutions are inadequate, serving patient populations across the United States and internationally. The company's flagship product is LUPKYNIS, an approved treatment designed for adult individuals suffering from active lupus nephritis. Furthermore, Aurinia maintains a strategic collaboration and licensing agreement with Otsuka Pharmaceutical Co., Ltd. The firm's main corporate office is located in Victoria, Canada.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Peter S. Greenleaf | Consultant | 1970 | $1,700,080 USD |
| Stephen Robertson | Chief Legal Officer, Corporate Secretary & Chief Compliance Officer | 1982 | $923,480 USD |
| Michael S. Hearne | Chief Financial Officer | 1963 | $866,870 USD |
| Kevin C. Tang | Chairman & CEO | 1967 | – |
| Ryan Cole | Chief Operating Officer | 1987 | – |
| Stewart Kroll | Chief Development Officer | 1959 | – |
| Thomas Wei | Chief Scientific Officer | 1976 | – |